Pathways influencing left ventricular hypertrophy in hemodialysis patients

心脏几何结构异常在接受透析的患者中很常见， 导致每年15- 20%的高死亡率。频繁的血液透析 网络旨在以随机方式测试更频繁的透析（无论是以 夜间透析和短期每日透析）将改善患者的心脏几何形状， 他们对自己身体健康的主观看法。结合阿尔伯塔肾 疾病网络，我们的研究小组可以访问存储的血清样本，从243 参加频繁血液透析网络和阿尔伯塔肾脏的患者 疾病网络试验。目前的研究应用将检查储存的血液 这些参与者的样本，以分析频繁透析与 血液中一组物质（称为生物标志物）的标准透析， 与异常心脏几何结构的发展有关。为了获得更多的 了解频繁透析与标准透析影响背后的生物学 透析心脏发育，我们还将研究来自大鼠心脏的细胞是否会 在将这些细胞暴露于血清样品后改变特定基因的表达， 在治疗期间心脏几何结构改善或恶化的患者 频繁血液透析网络或阿尔伯塔肾脏疾病网络试验。 因此，本申请具有两个具体目的： 目的1：我们将调查参与者的血液生物标志物水平， 血液透析网络和阿尔伯塔肾脏疾病网络试验的类型 分配的透析（频繁与标准）及其心脏几何结构的变化。 目的2：我们将检测来自大鼠心脏的细胞是否会表达不同的基因， 暴露于心脏几何结构进展患者和 在频繁血液透析网络或阿尔伯塔期间， 肾脏疾病网络试验。 我们的研究团队拥有最大的生物样本收集， 全球强化血液透析试验的参与者。我们已经聚集了 完成拟定研究目的所需的临床和科学专业知识。的 这项辅助研究提案的结果将提供独特的生物学见解， 机制和潜在的治疗目标，以改善患者的健康接受 透析在北美

Abnormal heart geometry is common among patients receiving dialysis and contributes to the high annual mortality rate of 15-20%. The Frequent Hemodialysis Network aims to test in a randomized fashion if more frequent dialysis (both in the form of nightly dialysis and short daily dialysis) will improve our patients¿ heart geometry and their subjective view of their physical health. In combination of the Alberta Kidney Disease Network, our research team has access to stored serum samples from 243 patients who participated in the Frequent Hemodialysis Network and the Alberta Kidney Disease Network Trials. The present research application will examine stored blood samples from these participants to analyse the effect(s) of frequent dialysis versus standard dialysis on a panel of substances in the blood (known as biomarkers), which are linked with the development of abnormal heart geometry. In order to gain further understanding of the biology behind the impact of frequent dialysis versus standard dialysis on heart development, we will also examine if cells derived from rat hearts will change the expression of specific genes after exposing these cells to serum samples of patients who have either improvement or deterioration of heart geometry during the Frequent Hemodialysis Network or Alberta Kidney Disease Network Trials. The present application therefore has two specific aims: Aim 1: We will investigate the blood levels of biomarkers in participants of the Frequent Hemodialysis Network and Alberta Kidney Disease Network Trials in relation to the type of dialysis (frequent versus standard) assigned and their changes of heart geometry. Aim 2: We will examine if cells derived from rat hearts will express different genes after exposure to serum from patients whose heart geometry progressed and from patients whose heart geometry improved during the Frequent Hemodialysis Network or Alberta Kidney Disease Network Trials. Our research team has the largest collection of biological samples derived from participants of intensive hemodialysis trials worldwide. We have assembled the necessary clinical and scientific expertise to complete the proposed study aims. The results from this ancillary study proposal will provide unique biological insights into the mechanisms and potential therapeutic targets to improve the health of patients receiving dialysis in North America.